Sign in
ARQT Stock Price, Chart, Stats & News
Arcutis Biotherapeutics, Inc.
Save
3.34B
Market cap
–
Current P/E
144.93x
Forward P/E
ARQT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 90.24% |
Operating margin | -3.25% |
Pretax margin | -3.98% |
Net margin | -4.29% |
Effective tax rate | -7.82% |
ROA | -3.73% |
ROE | -10.26% |
D/E | 0.03x |
Interest coverage ratio | -1.01x |
ARQT valuation
P/E | – |
P/S | 7.00x |
P/B | 14.36x |
P/CF | -483.82x |
P/FCF | -417.05x |
P/OCF | -483.82x |
PEG | -2.64x |
EV multiple | 1013.53x |
About
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds.
Similar securities
Based on sector and market capitalization
Report issue